EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Reducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain

Nathan T Fiore, Kendal F Willcox, Dorsa Dayani, Younus A Zuberi, Cobi J Heijnen, Peter M Grace

Brain, Behavior, and Immunity · 2025-03 · 125 · 371-387

DOI: 10.1016/j.bbi.2025.01.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025-03. Verfasst von Nathan T Fiore und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratories of Neuroimmunology, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, USA. Hauptthemen laut MEDLINE: Receptors, Fc, Histocompatibility Antigens Class I, Immunoglobulin G, Neuralgia. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, US Department of the Army.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preclinical and clinical studies have established that autoreactive immunoglobulin G (IgG) can drive neuropathic pain. We recently demonstrated that sciatic nerve chronic constriction injury (CCI) in male and female mice results in the production of pronociceptive IgG, which accumulates around the lumbar region, including within the dorsal root ganglia (DRG) and spinal cord, facilitating the development of neuropathic pain. These data raise the intriguing possibility that neuropathic pain may be alleviated by reducing the accumulation of IgG. To this end, we tested whether biologic inhibition or genetic deletion of the neonatal Fc receptor (FcRn) would attenuate mechanical hypersensitivity (allodynia) and IgG deposition induced by CCI. FcRn are prominently expressed on myeloid and endothelial cells and extend the half-life of IgG via pinocytosis and recycling into the extracellular milieu. We show here that administration of the FcRn blocker efgartigimod either 7- or 28-days post-CCI relieved allodynia among both male and female mice, compared to the Fc fragment control. Efgartigimod, administered systemically (intraperitoneal) or to the lumbar region (intrathecal), attenuated mechanical allodynia for at least one month. CCI-induced allodynia was similarly reduced in FcRn-deficient (FcRn-) mice compared to wild-type mice. Biologic inhibition or genetic deletion of FcRn also reduced CCI-induced accumulation of IgG on macrophages and neurons in lumbar DRG, as well as microglia in the lumbar dorsal spinal cord. Expression of the Fc receptor γ subunit (FcRγ) was reduced in efgartigimod-treated or FcRn- mice post-CCI compared to controls. The FcRγ subunit is a key component of Fc gamma receptors (FcγRs), which are activated by IgG immune complexes. In macrophage cultures stimulated by IgG immune complexes, FcRn blockade also dampened FcγR-dependent production of proinflammatory cytokines. Collectively, our study demonstrates that FcRn blockade or deletion alleviates mechanical allodynia and reduces IgG accumulation after CCI, attenuating pronociceptive IgG-FcγR signaling around the lumbar region. Strategies to block FcRn and reduce IgG recycling warrant further investigation as potential treatments for IgG-mediated neuropathic pain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, FcHistocompatibility Antigens Class IImmunoglobulin GNeuralgiaAnimalsFemaleMaleMiceHyperalgesiaGanglia, SpinalMice, Inbred C57BLSpinal Cord

Stichwörter der Autor:innen

EfgartigimodFc gamma receptorImmunoglobulin GMonoclonal antibodyNeonatal Fc receptorNerve injuryPainProinflammatory cytokines

Substanzen

Receptors, FcFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin G

Autor:innen und Institutionen

  • Laboratories of Neuroimmunology, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Department of Psychological Sciences, Rice University, Houston, USA.
  • Laboratories of Neuroimmunology, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: PGrace@mdanderson.org.

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • US Department of the Army
  • National Institutes of Health
  • U.S. Department of Defense
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Fiore, N. T., Willcox, K. F., Dayani, D., Zuberi, Y. A., Heijnen, C. J., & Grace, P. M. (2025). Reducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain. Brain, Behavior, and Immunity, 125, 371-387. https://doi.org/10.1016/j.bbi.2025.01.015

Vancouver

Fiore NT, Willcox KF, Dayani D, Zuberi YA, Heijnen CJ, Grace PM. Reducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain. Brain, Behavior, and Immunity. 2025;125:371-387. doi:10.1016/j.bbi.2025.01.015

BibTeX
@article{Fiore2025,
  author = {Fiore, Nathan T and Willcox, Kendal F and Dayani, Dorsa and Zuberi, Younus A and Heijnen, Cobi J and Grace, Peter M},
  title = {Reducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain},
  journal = {Brain, Behavior, and Immunity},
  year = {2025},
  volume = {125},
  pages = {371--387},
  doi = {10.1016/j.bbi.2025.01.015}
}
Kostenlos starten →